



2/27/23

Vermont Attorney General's Office  
109 State Street  
Montpelier, VT 05609  
AGO.highcostprescriptiondrugs@vermont.gov

To Whom It May Concern:

As required by 18 V.S.A. § 4637(b), Apellis Pharmaceuticals, Inc. is providing notice of the introduction of a new prescription drug with a Wholesale Acquisition Cost that exceeds the threshold set for a specialty drug under the Medicare Part D program on 2/27/23. The new product being launched is Syfovre and the NDC # is 73606-0020-01.

Sincerely,

Michelle Cerruti  
Director, Government Pricing and Contract Operations